Top-News

Cardax News

Keine aktuellen Kursdaten verfügbar
ISIN: US14141D2018
US-Symbol: CDXI
Typ: Aktie

Cardax News

31.08.21 - PR Newswire
Cardax Refocuses on ZanthoSyn® Consumer Health Business
Cardax Refocuses on ZanthoSyn® Consumer Health Business Company focusing on consumer revenue growth with reduced cost structure
11.08.21 - PR Newswire
Cardax Voluntarily Suspends SEC Reporting Obligations
Cardax Voluntarily Suspends SEC Reporting Obligations Expected savings to support core business strategies PR Newswire
14.05.21 - PR Newswire
Cardax Reports Q1 2021 Results
Cardax Reports Q1 2021 Results - Operating loss decreased vs. Q1 2020 - Net loss increased vs. Q1 2020 - ZanthoSyn® revenues decreased vs. Q1 2020 - Company pursuing ...
15.04.21 - PR Newswire
Cardax Reports 2020 Results
Cardax Reports 2020 Results - Net loss and operating expenses decreased vs. 2019 - ZanthoSyn® revenues decreased vs. 2019 - Company pursuing multiple funding ...
13.11.20 - PR Newswire
Cardax Reports Q3 2020 Results
Cardax Reports Q3 2020 Results - Operating loss decreased vs. Q3 2019 - Net loss decreased vs. Q3 2019 - ZanthoSyn® revenues decreased vs. Q3 2019 - Cardax invited to ...
14.08.20 - PR Newswire
Cardax Reports Q2 2020 Results
Cardax Reports Q2 2020 Results - Operating loss decreased vs. Q2 2019 - Net loss increased vs. Q2 2019 - ZanthoSyn® revenues increased vs. Q2 2019 - Cardax submits invited ...
15.05.20 - PR Newswire
Cardax Reports Q1 2020 Results
Cardax Reports Q1 2020 Results PR Newswire
30.03.20 - PR Newswire
Cardax Reports 2019 Annual Results
Cardax Reports 2019 Annual Results - CHASE clinical trial interim review demonstrated beneficial changes in markers of cardiovascular health - Composition of matter patent for ...
20.03.20 - PR Newswire
Cardax Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease
Cardax Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease Cardax seeking strategic collaborations to further develop astaxanthin ...
14.01.20 - PR Newswire
Cardax, Inc. Announces Reverse Stock Split of Common Stock
Cardax, Inc. Announces Reverse Stock Split of Common Stock PR Newswire
14.11.19 - PR Newswire
Cardax Reports Q3 2019 Results
Cardax Reports Q3 2019 Results - CHASE clinical trial interim review demonstrated beneficial changes in markers of cardiovascular health - Composition of matter and use patents ...
23.09.19 - PR Newswire
Cardax Announces Interim Results from CHASE Clinical Trial
Cardax Announces Interim Results from CHASE Clinical Trial Pre-​Specified Interim Review Demonstrated Beneficial Changes in Markers of Cardiovascular Health - CRP, LDL, total ...
14.08.19 - PR Newswire
Cardax Reports Q2 2019 Results
Cardax Reports Q2 2019 Results - CHASE clinical trial progressing; interim review planned for September 2019 - $1,675,000 raised since beginning of Q2 2019 - ZanthoSyn® sell-...
14.08.19 - PR Newswire
Cardax Files Registration Statement for Proposed $15 Million Follow-On Offering
Cardax Files Registration Statement for Proposed $15 Million Follow-On Offering - Maxim Group to serve as sole book running manager on a firm commitment basis - Funds to be ...
17.05.19 - PR Newswire
Cardax Reports Q1 2019 Results
Cardax Reports Q1 2019 Results PR Newswire
28.03.19 - PR Newswire
Cardax Reports 2018 Results
Cardax Reports 2018 Results - Revenues More Than Doubled - CHASE Clinical Trial Initiated - Rx Development Plans for CDX-101 and CDX-301 Underway PR Newswire
13.11.18 - PR Newswire
Cardax Reports Q3 2018 Results
Cardax Reports Q3 2018 Results Robust ZanthoSyn® Sales Growth Continues - 102% Greater Than Q2 2018 - 71% Greater Than Q3 2017 - 129% 9-Month Sales Growth PR ...
02.10.18 - PR Newswire
Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health
Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health CHASE Trial to Evaluate Impact of ZanthoSyn® in Largest Astaxanthin Study Ever PR Newswire
13.08.18 - PR Newswire
Cardax Reports Q2 2018 Results
Cardax Reports Q2 2018 Results ZanthoSyn® Sales 4x Higher Than Q2 2017 PR Newswire
30.07.18 - PR Newswire
Cardax Announces Successful Completion of Warrant Exchange Offer
Cardax Announces Successful Completion of Warrant Exchange Offer Company Raises $1.44 Million in Non-​Dilutive Financing PR Newswire

Newssuche

Videos

09:10 Uhr 0,00%
Technical Trading: S&P 500 Short Chance
S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »